Drug-induced diabetes mellitus

  title={Drug-induced diabetes mellitus},
  author={Hassane Izzedine and Vincent Launay-Vacher and Camille Deybach and Edward Bourry and Beno{\^i}t Barrou and Gilbert Deray},
  journal={Expert Opinion on Drug Safety},
  pages={1097 - 1109}
Aims: To review the medications that influence glucose metabolism with a focus on hypertensive, transplant and HIV-infected patient populations. Methods: Literature obtained from a MEDLINE search from 1970 to present, including studies published in the English language. The search strategy linked drugs, hyperglycaemia and diabetes mellitus, HIV, transplantation, hypertension and psychiatric patients. Results: Many common therapeutic agents influence glucose metabolism. Multiple mechanisms of… 

Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives

The genetic basis of drug-induced diabetes is elucidated and the way for the precise use of these drugs in the clinic is paved, including calcineurin inhibitors, antipsychotics, hormones, and antihypertensive drugs.

Assessment of Plasma level of Nesfatin-1 in newly diagnosed Type 2 Diabetic patients

The novelty of this study is that it showed, for the first time, significantly lower nesfatin-1 levels in diabetic patients but less lower in prediabetic patients (IGT).

Hypertension in Children with the Metabolic Syndrome or Type 2 Diabetes

A comprehensive approach, including non-pharmacologic measures, hypoglycemic and antihypertensive medications, and perhaps even bariatric surgery in selected patients, is indicated in order to reduce future cardiovascular risk.

Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms

Management of hypertension in children and adolescents with the metabolic syndrome.

Several aspects of the approach to treatment of hypertension in young patients with the metabolic syndrome are highlighted, including the definition of hypertension, use of nonpharmacologic measures, indications for instituting antihypertensive medications, and the potential adjunctive role that insulin-sensitizing agents may play in blood pressure reduction.

Drug-induced diabetes type 2: In silico study involving class B GPCRs

The study showed that incretin hormone receptors, named also gut hormone receptors as they are expressed in the gastrointestinal tract, could potentially act as unintended targets for orally administrated drugs and suggested that those strongly binding molecules could potentially stimulate GIPR and GLP1R and/or inhibit GCGR which could lead to increased insulin secretion and decreased hepatic glucose production.

Evaluation of admission glucose profile and glycosylated hemoglobin: factors associated with glucose metabolism should be assessed.

It could be concluded that AGP and HbA1c have not sufficient power to screen and predict short-term cardiac complications after AMI, and AGP is a good predictor for AMI complications, significantly better for electrical complications.

Pharmacologically-Induced Metabolic Acidosis

Determinations of arterial blood gases, the serum anion gap and the serum osmolar gap are helpful in delineating the pathogenesis of the acid-base disorder, and in all cases of drug-related metabolic acidosis, discontinuation of the culprit medications and avoidance of readministration is advised.

Drug-induced liver injury in obesity.



Drug-Induced Disorders of Glucose Tolerance

This review examines medications that may alter glucose insulin homeostasis and discusses possible mechanisms of action at the potential sites at which medication may induce changes in glucose metabolism.

Drug-Induced Disorders of Glucose Metabolism

The hypoglycaemic effects of a drug may be turned to a therapeutic advantage in patients with diabetes mellitus or those who are at risk of developing glucose intolerance, despite the large number of anecdotal reports of drug-induced disturbances of glucose metabolism.

New strategies for basal insulin treatment in type 2 diabetes mellitus.

Consensus development conference on antipsychotic drugs and obesity and diabetes.

A consensus position is developed on the relationship between the second-generation antipsychotics (SGAs) and the development of major CVD risk factors, including obesity, diabetes, and dyslipidemia.

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.

Increased risk of non‐insulin-dependent diabetes mellitus in elderly hypertensive subjects

The data presented suggest that the increased risk of NIDDM in hypertensive subjects taking β-blockers or diuretics, or both, is explained at least partly by metabolic disturbances related to drug therapy.

Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment.

Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol study

It is demonstrated that a β-blocker with α1-blocking properties has favorable effects on glucose metabolism, suggesting a potentially important role of peripheral blood flow in regulating glucose uptake.

Metabolic consequences of antihypertensive therapy.

The abnormalities in lipid metabolism, carbohydrate tolerance, and changes in the renin-angiotensin-aldosterone axis are reviewed and their exact role in hypertensive cardiovascular disease remains to be elucidated.

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

By improving glucose and lipid metabolism and reducing lipid peroxidation, carvedilol may offer advantages in patients with diabetes and hypertension.